9 research outputs found
The outcome of a surgical protocol based on ischemia overprotection in large and giant aneurysms of the anterior cerebral circulation
Cost-effectiveness analysis of treatment for Koos 2 and 3 vestibular schwannomas: Wait & scan or radiosurgery
Objective: Vestibular schwannomas are benign slowly growing tumors, with 3 treatment options: wait and scan, radiosurgery, and microsurgery with specific advantages and disadvantages. Contemporary debate has focused on medium size tumor. The present study used a Markov model to try to identify the cost-effectiveness in a lifelong perspective of the “wait & scan” or “radiosurgery” strategies for Koos 2 and 3 tumors. Methods: The present model was defined by 5 discrete health states. All decision and chance nodes were assigned a probability of occurrence derived from a thorough review of the related literature. We calculated the expected effects and costs associated with the two strategies, then evaluated the incremental cost-effectiveness ratio. Sensitivity analysis was performed by altering the input values within a clinically reasonable range to assess the effects of uncertainties. Results: Radiosurgery always requires more costs than wait & scan, and seems to generate small effects. However, the incremental cost-effectiveness ratio was significantly influenced by the hazard ratio of risk generated by deferred radiosurgery. One-way and two-way sensitivity analysis indicated that radiosurgery always yields negative effectiveness, compared with wait & scan at hazard ratio of less than 3.0, regardless of any other assumptions. Conclusions: Treatment strategy for medium size vestibular schwannoma should primarily be based on the future increased risk of radiosurgery after failure of conservative management. Wait & scan strategy may be the optimum approach for most Koos 2 and 3 tumors, but relatively large Koos 3 tumors are candidates for immediate radiosurgery
Pontine venous congestion due to dural arteriovenous fistula of the cavernous sinus: Case report and review of the literature
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial.Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib.Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (< 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without.Conclusion: Baseline low serum CXCL9 (< 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
Simple Summary The IMbrave150 trial led to the approval of atezolizumab and bevacizumab for the treatment of unresectable hepatocellular carcinoma (HCC). We performed a retrospective multicenter study including 115 patients with unresectable HCC treated with atezolizumab and bevacizumab, revealing that the combination of atezolizumab and bevacizumab is equally effective for patients meeting the IMbrave150 trial eligibility criteria and for patients not meeting these criteria, generally due to a history of systemic therapy, platelet counts < 75 x 10(9)/L, Child-Pugh B, and 2+ proteinuria. However, liver functional reserve should be carefully monitored in patients not meeting the IMbrave150 trial eligibility criteria. The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 x 10(9)/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 +/- 0.43 vs. -2.18 +/- 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed